Study guide
25.1 Close-Out, Archiving and Continuing Obligations
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
25.1 Close-Out, Archiving and Continuing Obligations
Key Takeaways Explain This Topic AI
Closure should address participant care, product disposition, records and relevant final notifications.
Custodian, location and continued access need to remain clear.
Retention follows applicable periods or sponsor release, whichever is longer.
Last updated: October 2026
Close-Out, Archiving and Continuing Obligations
The monitor verifies that all central laboratory collection kits have been utilized, returned, or disposed of according to biohazard protocols. Sponsor-loaned equipment—such as dedicated clinical trial laptops, electronic tablets, automated blood pressure cuffs, or calibrated 12-lead ECG devices—are sanitized, decontaminated, and shipped back to the sponsor or equipment vendor.
Confidential linkage and continuing access
Retain the participant identification code list securely at the investigator/institution as appropriate. It must support authorised traceability while preventing inappropriate disclosure. A sealed envelope is one possible paper method, not a universal ICH requirement. Controlled electronic storage can also be appropriate. Record the custodian and retrieval route.
Final Notification to the Institutional Review Board (IRB/IEC)
Under ICH E6(R3), upon completion of the trial, the investigator must inform the institution and promptly provide the IRB/IEC with a summary of the trial's outcome. The PI transmits a formal Final Study Closure Report to the IRB, summarizing the total number of subjects enrolled, completed, discontinued, and any late-emerging safety events. Retain the submission and any relevant acknowledgement or decision under the applicable process.
Record Retention and Archiving
Once the Site Close-Out Visit is complete, relevant clinical trial records—including the ISF, signed informed consent forms, original medical charts, laboratory printouts, and pharmacy logs—must remain securely retained for the required period, including in appropriate existing systems.
Retention and controlled destruction
E6(R3) requires investigator/institution records to be retained for the period required by applicable regulations or until the sponsor says they are no longer needed, whichever is longer . Do not substitute an old R2 two-year mnemonic for the current rule or infer that two years after site close-out is sufficient.
At closure document the custodian, location, retrieval process, permitted access and continued readability of paper and electronic records. Protect against unauthorised access, accidental loss and premature destruction. Record a transfer of custody or relocation and inform relevant parties. Data, metadata and audit trails needed for reconstruction belong in the retention plan.
Before destruction, confirm that all applicable retention periods, sponsor requirements and relevant holds have ended, obtain the required authorisation and document the disposition. Sponsor release cannot override a longer applicable legal period. A storage invoice or expired software licence is not authority to delete records.
Physical Archival Requirements
Archived records should be stored with suitable protection, which can include:
Environmental controls (climate, humidity, and pest control).
Physical fire suppression systems and flood protection.
Locked, access-restricted entry permitted only to designated archival custodians.
Written contractual commitment from the investigator that records will not be destroyed, relocated, or transferred to another institution without prior written authorization from the sponsor.
Early closure and outstanding obligations
An under-enrolling site can be closed before the global trial ends. Confirm whether it has participants requiring continued care or follow-up, unresolved safety cases, outstanding data questions or product needing disposition. Assign these obligations explicitly and preserve appropriate system/source access. A close-out visit records the situation and plan; it does not make unfinished work disappear.
When a site has no participants, some participant-level checks will be inapplicable, but agreements, approvals, supplies, system access and essential-record obligations can still matter. Document why a record or activity is not applicable rather than filling a generic checklist with unsupported completion marks. Retain a useful route for later inspection and questions.
If records or responsibility transfer to another person or institution, identify the custodian and confirm continuity before removing old access or returning equipment containing necessary information. Acknowledged handover and retrievable evidence are stronger than an email saying the study is closed. Verify completion of agreed follow-up through the responsible functions.
Closure starts a continuing records obligation
Essential records must remain complete, readable, retrievable and protected after routine trial activity ends. E6(R3) requires investigator/institution records to be retained for the period required by applicable regulations or until the sponsor informs the institution that they are no longer needed, whichever is longer. Do not use an old two-year R2 mnemonic or count a universal period from the close-out visit.
The retention plan should identify the records, responsible custodian, locations, formats, access arrangements and applicable periods. Include source, essential correspondence, data and relevant metadata/audit trails. Sponsor, site and service-provider responsibilities need to be clear. A portal used during the study may close before the required retention period ends, so continued access cannot depend on an untested promise.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 .